Newcastle Confidence in Concept 2017
Lead Research Organisation:
Newcastle University
Department Name: UNLISTED
Abstract
Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.
Technical Summary
The Confidence in Concept scheme is a key part of MRC’s translational research strategy and provides annual awards to institutions, to be used flexibly to support the earliest stages of multiple translational research projects. The award can be used by the institution to support a number of preliminary-stage translational projects. The projects supported should aim to provide sufficient preliminary data to establish the viability of an approach –– before seeking more substantive funding. It is intended to accelerate the transition from discovery research to translational development projects by supporting preliminary work or feasibility studies to establish the viability of an approach.
Organisations
Publications

Al Alawi I
(2021)
Case Report: A Novel In-Frame Deletion of GLIS2 Leading to Nephronophthisis and Early Onset Kidney Failure.
in Frontiers in genetics

Barroso-Gil M
(2021)
Update of genetic variants in CEP120 and CC2D2A-With an emphasis on genotype-phenotype correlations, tissue specific transcripts and exploring mutation specific exon skipping therapies.
in Molecular genetics & genomic medicine

Bashford J
(2020)
Excitability in amyotrophic lateral sclerosis: What goes up must come down.
in Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology

Cardenas-Rodriguez M
(2021)
Genetic compensation for cilia defects in cep290 mutants by upregulation of cilia-associated small GTPases.
in Journal of cell science

Choudhury S
(2019)
Slowed Movement Stopping in Parkinson's Disease and Focal Dystonia is Improved by Standard Treatment.
in Scientific reports

Connelly C
(2023)
O043 Evaluation of minimal factor H therapy administered to kidneys during ex vivo normothermic perfusion as a treatment to improve ischaemia reperfusion injury
in British Journal of Surgery



Ding Y
(2023)
An open source pipeline for quantitative immunohistochemistry image analysis of inflammatory skin disease using artificial intelligence.
in Journal of the European Academy of Dermatology and Venereology : JEADV
Description | A pilot study for a national screening programme of urothelial cancers in Lynch syndrome based on urine analysis using the Newcastle MSI-Plus assay |
Amount | £50,467 (GBP) |
Organisation | SBRI Healthcare |
Sector | Private |
Country | United Kingdom |
Start |
Description | ASO therapies in Joubert syndrome |
Amount | £100,000 (GBP) |
Organisation | LifeArc |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 03/2023 |
Description | Developing chemical probes to distinguish CDK4-cyclin D |
Amount | £122,979 (GBP) |
Organisation | Cancer Research UK |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 09/2020 |
End | 09/2024 |
Description | Developing non-invasive methods for early detection of Lynch Syndrome cancers using liquid biopsy |
Amount | £171,124 (GBP) |
Organisation | Barbour Foundation |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start |
Description | Dissemination of the Newcastle MSI-PLUS assay for Lynch syndrome screening and therapeutic targetting. |
Amount | £1,800,000 (GBP) |
Organisation | SBRI Healthcare |
Sector | Private |
Country | United Kingdom |
Start |
Description | Innate interferons in epithelial defence against respiratory viruses |
Amount | £176,474,894 (GBP) |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start | 02/2023 |
Description | Kidneeds - Title - Evaluation of HDM-FH gene therapy in pre-clinical models |
Amount | $75,000 (USD) |
Organisation | Kidneeds |
Sector | Charity/Non Profit |
Country | United States |
Start | 03/2023 |
Description | LifeArc Pathfinder) Homodimeric mini-FH gene therapy: safety, efficiency and added value |
Amount | £50,000 (GBP) |
Organisation | LifeArc |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 03/2023 |
Description | Medical Research Council (MRC) -MR/X020975/1 - Using mouse models to establish the effectiveness of gene therapy in the treatment of renal diseases. |
Amount | £763,000 (GBP) |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start | 04/2023 |
Description | Novel MRI Biomarkers in Neuromuscular Disease |
Amount | £117,300 (GBP) |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start |
Description | Pre-transplant microRNA blockade using direct Antisense Oligonucleotide delivery during Ex Vivo Normothermic machine Perfusion of kidneys |
Amount | £140,193 (GBP) |
Organisation | Kidney Research UK |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start |
Description | Rare Disease Node |
Amount | £1,200,000 (GBP) |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start | 06/2023 |
Description | SBRI 18 Phase 2 Stroke & Technology |
Amount | £798,919 (GBP) |
Organisation | SBRI Healthcare |
Sector | Private |
Country | United Kingdom |
Start | 11/2022 |
End | 11/2023 |
Description | Therapeutic monitoring by measuring the mouse complementome |
Amount | £238,000 (GBP) |
Organisation | Kidney Research UK |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 05/2023 |
Description | Using minimal Factor H therapy and normothermic conditions to prepare kidneys for transplantation |
Amount | £897,000 (GBP) |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start |
Description | Using structural and chemical biology to understand the roles and mechanisms of CDKs: generating hypotheses for drug discovery |
Amount | £1,914,754 (GBP) |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start | |
End | 07/2026 |
Title | METHOD OF IDENTIFYING COMPLEMENT MODULATORS (Amended) |
Description | Aspects of the present invention relate to method and systems which provide extended capability, compared to the existing techniques, for the screening of epitopes associated with complement activation. Particularly, but not exclusively, certain embodiments of the present invention relate to a method for generating a complement panning surface. Certain embodiments involve the use of surface plasmon resonance, and/or phage display technology. Certain embodiments of the present invention may be advantageous over the prior art in the generation of new complement panning surfaces. These surfaces may enable the identification of neoepitopes associated with surface-bound activated complement components. Compared to previous 'homing' complement drugs, such as TT30 - which target epitopes found on both soluble and surface-bound, activated complement components - the selective binding of only surface-bound activated components may result in said compound eliciting a longer-lasting therapeutic effect. This could potentially improve the compound's efficacy as a complement-modulating drug by extending the therapeutic window. |
IP Reference | PCT/GB2021/051359 |
Protection | Patent / Patent application |
Year Protection Granted | 2022 |
Licensed | No |
Impact | Not known as yet |
Description | Invited talk to a national specialist stroke meeting Prehospital selection and redirection in the NHS |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Professional Practitioners |
Results and Impact | Delivered a talk on Pre- hospital selection and redirection in the NHS. Sparked questions and answers and general discussion. |
Year(s) Of Engagement Activity | 2022 |
Description | Invited talk to the Welsh Stroke Conference |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | Delivering efficient emergency prehospital stroke care. Generated Questions and answers from the audience and also discussion during the day. |
Year(s) Of Engagement Activity | 2022 |
URL | https://healthandcareresearchwales.org/about/events/welsh-stroke-conference |
Description | Talk at American Society of Nephrology Annual Meeting Oct 2022 |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | Presentation and discussions at the event with networking opportunities during the event. |
Year(s) Of Engagement Activity | 2022 |
URL | https://www.asn-online.org/education/kidneyweek/2022/meeting-overview.aspx |
Description | Talk at EMBO CILIA Cologne Oct 2022 |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | 4 day event. Presentation given which generated question and answers and a great opportunity for networking |
Year(s) Of Engagement Activity | 2022 |
URL | https://www.cilia2022.de/ |
Description | Talk at RSM Nephrology London Dec 2022 |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | Presentation given which then generated question and answer session. Networking also took place during the event. |
Year(s) Of Engagement Activity | 2022 |
URL | https://www.rsm.ac.uk/events/nephrology/2022-23/ner03/ |
Description | Talk at Rare Disease MRC meeting |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | A presentation by Professor John Sayer (Professor of Renal Medicine Bioscience, Newcastle University) explained the work they are doing in funding rare disease research, and explained more about the MRC-NIHR rare diseases research platform. |
Year(s) Of Engagement Activity | 2023 |
Description | UK Cilia meeting October 2023 |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | CILIAREN, Renal Ciliopathies National Network launch - Presentation given which generated question and answers and a great opportunity for networking |
Year(s) Of Engagement Activity | 2023 |
URL | https://www.cilianetwork.org.uk/events/4659/annual-uk-cilia-network-one-day-meeting-in-person |